

## **Tinea Cruris: A Comprehensive Review of Clinical Features, Management Approaches and Homoeopathic Perspectives**

**Dr . Ishan Srivastava<sup>1\*</sup>**

<sup>1\*</sup>Ph. D Scholar Tania Universty, Under the Guidance of Prof. Dr . Muktesh Arora

### **Abstract**

Tinea cruris, commonly known as jock itch, is a prevalent fungal infection affecting the groin region. This review examines the current understanding of its etiology, epidemiology, clinical presentation, and treatment options, including both conventional and homeopathic approaches. Recent developments in diagnostic techniques and emerging therapeutic strategies are also discussed.

**Keywords:-**Tinea Cruris, Homoeopathy, Dermatophytosis

### **Introduction**

Tinea cruris commonly referred to as jock itch, tinea cruris is a fungal skin condition that affects the groin area. This infection, caused by organisms called dermatophytes, typically impacts the skin around the genitals, inner thighs, and buttocks. The condition can cause discomfort in the affected regions, including the pubic area and the skin between and around the buttocks. [1][2][3][4][5] Fungi known as dermatophytes specifically target structures containing keratin, including hair and the outer most layer of skin (stratum corneum), causing distinctive skin rashes. Areas where skin surfaces meet and rub together (intertriginous zones) create ideal conditions for fungal growth. The groin area is particularly susceptible to these infections due to several factors: moisture from perspiration, skin breakdown from friction (maceration), and a higher pH level that favors fungal development. [1][2][3][4]

Although the location of the infection on the body is one way to categorize tinea conditions, they can also be categorized based on how the fungus spreads and where it originally comes from. Understanding both the affected body part and the source of the infectious organism helps in classifying these fungal infections more comprehensively.[3] Geophilic, zoophilic, and anthropophilic fungi are found in and transmitted by soil, animals, and humans, respectively.[1][3][6][7] A person can inadvertently spread fungal infections to different parts of their own body, which is particularly significant in cases of jock itch. For instance, someone with athlete's foot might unintentionally transfer the fungus from their feet to their groin area, leading to a secondary infection in that region.[1]

### **Etiology**

Tinea cruris is caused by dermatophytes belonging to three genera, Trichophyton, Epidermophyton, and Microsporum.[5] Globally, the predominant pathogen identified in cases of tinea cruris is Trichophyton rubrum. However, research indicates a shifting pattern in some geographical areas, with an uptick in infections caused by Trichophyton mentagrophytes and various other fungal organisms. This changing landscape of causative agents highlights the importance of considering multiple potential pathogens when diagnosing and treating groin fungal infections.[1][2][3][4][7] Multiple factors can increase a person's likelihood of developing tinea cruris. These include heavy sweating, wearing tight or non-breathable clothing, inadequate personal hygiene practices, and certain health conditions such as diabetes. Additionally, individuals with weakened immune systems face a higher risk of infection. Socioeconomic factors also play a role, with those in lower-income situations potentially being more vulnerable to developing this fungal condition. [1][2][3][6]

People who participate in athletic activities, particularly those that involve physical contact with others, face a higher risk of developing fungal skin infections. The nature of contact sports can create conditions that make athletes more vulnerable to these types of skin conditions. ] Genetics can also make a patient more disposed to dermatophytes.[3][6] all these factors, perspiration appears to be the most influential variable in the development of infection.[1][8] A research investigation was launched in India due to growing concerns about dermatophyte infections. The country experiences a notably high burden of these fungal conditions compared to other regions. The study was prompted by two alarming trends: the rising number of cases and the declining effectiveness of traditional treatment approaches for local fungal skin infections. Research has identified several factors associated with persistent or recurring fungal infections. These include having diabetes, living with family members who have tinea infections, and regularly

preparing meals. These conditions may contribute to making the infections more difficult to eliminate completely and more likely to return.[ 9]

### **Epidemiology**

Globally, Cutaneous mycoses, including tinea cruris infections, impact 20-25% of people worldwide [3][10]. Environmental factors like high temperatures and moisture levels make developing countries and humid regions more susceptible to dermatophyte infections [1][11]. Statistics from the United States indicate approximately 29.4 million cases of surface-level fungal infections, resulting in over 51 million doctor visits [6]. The condition predominantly affects males, particularly during adolescence and adulthood [1][2][11]. The growing prevalence of dermatophyte infections globally, along with the emergence of treatment-resistant cases, has become a significant health concern worldwide [3][4][5][9].

### **Pathophysiology**

The way dermatophyte fungi cause infection, while not fully understood, can be explained in basic terms. These organisms produce special enzymes called proteinases that break down keratin, a protein found in the outermost layer of skin (stratum corneum) [6][12][7]. This ability to digest skin proteins allows the fungi to establish and spread their infection.

### **Histopathology**

Although not typically required for diagnostic purposes, examining skin samples treated with potassium hydroxide (KOH) can reveal tissue characteristics typical of fungal infections [1][2][3]. When viewed under a microscope, distinctive features may be observed, such as segmented fungal filaments (hyphae) that may or may not branch, and potentially fungal spores called arthroconidiospores [2][3].

### **Clinical Assessment**

When seeking medical attention, individuals with jock itch typically describe an itchy skin eruption in the groin region [1][2]. The affected area may be sore and painful, particularly if skin breakdown occurs, and secondary infections can lead to inflammation and discomfort [2]. Medical professionals should gather information about symptom duration, previous episodes, similar rashes elsewhere on the body, and treatments already attempted. It's important to screen for underlying conditions such as diabetes, immune disorders, kidney disease, or liver problems [13]. Questions about perspiration patterns, clothing choices, and personal cleanliness routines are relevant. Understanding potential exposure sources, including contact with people, household pets, other animals, or contaminated earth, may provide valuable insights [13].

During the physical assessment, healthcare providers typically observe a red, scaly, ring-shaped patch with raised borders and clearer skin in the center. This rash can spread across the groin, upper thighs, perineum, and the area around the anus [1][2].

### **Diagnosis and Investigation**

Typically, tinea cruris can be identified through clinical evaluation; however, various diagnostic tools are available to examine unexplained groin rashes.[1][2][3] Potassium hydroxide (KOH) preparations, skin biopsy with periodic acid-Schiff (PAS) stain, and fungal cultures on Sabouraud's agar media can be employed when diagnosis is uncertain or in cases of persistent or treatment-resistant episodes.[1][2][3]

### **Therapeutic Management**

Antifungal medications used to treat dermatophytoses, including tinea cruris, target ergosterol synthesis, a critical component of fungal cell membranes.[4] Treatment strategies are largely consistent worldwide, although regional fungal profiles may influence specific guidelines.[6] Topical treatments are generally effective and preferred.[2][4][6] Allylamines (terbinafine, butenafine, naftifine) and azoles (clotrimazole, miconazole, sulconazole, oxiconazole, econazole, ketoconazole) are primary topical treatment options. They are usually prescribed once or twice daily for two to four weeks.[1][3][6]

### **Treatment Selection**

The choice of treatment should be based on patient adherence, cost, and medication accessibility, as there is insufficient evidence to directly compare individual medication efficacy.[8][15][16][13] Allylamines offer potentially shorter treatment durations and lower relapse rates, with metabolism independent of the cytochrome p450 system.[8][13] Azoles are less expensive but often require longer treatment periods.[8] Luliconazole, a newer topical azole, requires only once-daily application for one week, potentially enhancing patient compliance.[6] Ciclopirox olamine is an older topical preparation with a distinct mechanism of action.[17]

### **Systemic Treatment**

Oral preparations are available for managing tinea cruris, particularly for chronic, recurrent, or treatment-resistant cases.[1][2][4][6] Extensive or diffuse rashes and immunocompromised patients may also require systemic treatment.[4] Oral terbinafine and itraconazole are commonly prescribed due to their favorable characteristics.[4][15][16][13]

### **Differential Diagnosis**

Tinea cruris can be confused with various dermatological conditions affecting the groin, including candidiasis, erythrasma, psoriasis, and seborrheic dermatitis.[1][2] A thorough evaluation is necessary to distinguish between these conditions.

### **Prognosis and Outcomes**

Patients with tinea cruris who receive appropriate treatment experience cure rates ranging from 80 to 90 percent.[19]

### **Potential Complications**

Treatment failure and recurrence are common complications of tinea cruris, often due to reinfection, misdiagnosis, or non-adherence to treatment plans.[3] Secondary bacterial infections and Majocchi's granuloma are additional potential complications.[3][20]

### **Preventive Measures and Patient Education**

Patient education should emphasize non-pharmacological measures to prevent recurrences. Loose-fitting clothing, complete skin drying before dressing, and avoiding barefoot walking in public facilities can help prevent tinea cruris.[3][13] Self-treatment with over-the-counter medications should be discouraged to avoid resistant or chronic infections.[4]

### **Homeopathic Remedies for Tinea Cruris [15][16][17][18]**

#### **1. Arsenicum Album**

Suitable for individuals with syphilis miasm, anxiety, fear of death, and restless disposition. Characterized by extreme chilliness, dry scaly skin, herpetic eruptions at the groin region with itching and burning. Relief from heat.

#### **2. Bacillinum**

Effective for eruptions at the groin region with itching, Pityriasis infection, and eczema of eyelids. Symptoms worsen at night, early morning, and in cold air.

#### **3. Dulcamara**

Predominant miasm: Psora and Sycosis. Chilly patients with catarrhal skin affections triggered by cold, damp, or sudden weather changes. Humid eruptions on the face and groin region.

#### **4. Graphitis**

Predominant miasm: Psora. Suitable for fatty, flabby, chilly individuals with costive tendencies. Skin inclined to crack, fissures, and eruptions on various body parts.

#### **5. Natrum Muriaticum**

Covers all three miasms. Suitable for anaemic, chlorotic, and emaciated individuals. Herpes around the anus and hairline.

#### **6. Natrium Sulphuricum**

Predominant miasm: Sycosis. Chilly patients with diseases triggered by damp weather. Violent itching in genital organs and between toes.

#### **7. Petroleum**

Predominant miasm: Psora and Syphilis. Herpes on genital organs, skin cracked, rough, and bleeding.

#### **8. Sepia**

Predominant miasm: Psora and Sycosis. Suitable for pot-bellied mothers with chronic uterine troubles. Herpes circinatus and itching of skin.

#### **9. Sulphur**

Predominant miasm: Psora. Suitable for lean individuals with stooped shoulders. Voluptuous itching, scratching causes burning.

#### **10. Tellurium Metallicum**

Predominant miasm: Psora. Herpes circinatus, itching of hands, feet, and groin region.

#### **11. Tuberculinum**

Indicated for individuals with tubercular diathesis, intense itching, and white bran-like scales.

## REFERENCES

1. Gupta AK, Chaudhry M, Elewski B. Tinea corporis, tinea cruris, tinea nigra, and piedra. *Dermatol Clin*. 2003 Jul;21(3):395-400, v. [[PubMed](#)]
2. Ely JW, Rosenfeld S, Seabury Stone M. Diagnosis and management of tinea infections. *Am Fam Physician*. 2014 Nov 15;90(10):702-10. [[PubMed](#)]
3. Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. *Indian Dermatol Online J*. 2016 Mar-Apr;7(2):77-86. [[PMC free article](#)] [[PubMed](#)]
4. Khurana A, Sardana K, Chowdhary A. Antifungal resistance in dermatophytes: Recent trends and therapeutic implications. *Fungal Genet Biol*. 2019 Nov;132:103255. [[PubMed](#)]
5. Sardana K, Kaur R, Arora P, Goyal R, Ghunawat S. Is Antifungal Resistance a Cause for Treatment Failure in Dermatophytosis: A Study Focused on Tinea Corporis and Cruris from a Tertiary Centre? *Indian Dermatol Online J*. 2018 Mar-Apr;9(2):90-95. [[PMC free article](#)] [[PubMed](#)]
6. Gupta AK, Foley KA, Versteeg SG. New Antifungal Agents and New Formulations Against Dermatophytes. *Mycopathologia*. 2017 Feb;182(1-2):127-141. [[PubMed](#)]
7. Odom R. Pathophysiology of dermatophyte infections. *J Am Acad Dermatol*. 1993 May;28(5 Pt 1):S2-S7. [[PubMed](#)]
8. Nadalo D, Montoya C, Hunter-Smith D. What is the best way to treat tinea cruris? *J Fam Pract*. 2006 Mar;55(3):256-8. [[PubMed](#)]
9. Singh S, Verma P, Chandra U, Tiwary NK. Risk factors for chronic and chronic-relapsing tinea corporis, tinea cruris and tinea faciei: Results of a case-control study. *Indian J Dermatol Venereol Leprol*. 2019 Mar-Apr;85(2):197-200. [[PubMed](#)]
10. Ameen M. Epidemiology of superficial fungal infections. *Clin Dermatol*. 2010 Mar 04;28(2):197-201. [[PubMed](#)]
11. Vena GA, Chieco P, Posa F, Garofalo A, Bosco A, Cassano N. Epidemiology of dermatophytoses: retrospective analysis from 2005 to 2010 and comparison with previous data from 1975. *New Microbiol*. 2012 Apr;35(2):207-13. [[PubMed](#)]
12. Samdani AJ. Dermatophyte growth and degradation of human stratum corneum in vitro (pathogenesis of dermatophytosis). *J Ayub Med Coll Abbottabad*. 2005 Oct-Dec;17(4):19-21. [[PubMed](#)]
13. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hardinsky MK, Lewis CW, Pariser DM, Skouge JW, Webster SB, Whitaker DC, Butler B, Lowery BJ, Elewski BE, Elgart ML, Jacobs PH, Leshner JL, Scher RK. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guidelines/Outcomes Committee. American Academy of Dermatology. *J Am Acad Dermatol*. 1996 Feb;34(2 Pt 1):282-6. [[PubMed](#)]
14. Raghukumar S, Ravikumar BC. Potassium hydroxide mount with cellophane adhesive tape: a method for direct diagnosis of dermatophyte skin infections. *Clin Exp Dermatol*. 2018 Dec;43(8):895-898. [[PubMed](#)]
15. Allen J.H.; *The chronic Miasms with Repertory*; Revised edition – 1998; B. Jain publishers Pvt. Ltd, New Delhi; 2007; Page No. 94
16. Allen HC.; *Keynotes and characteristics with comparisons of the leading remedies of the materia medica*; 11th impression; 2012. B. Jain Publishers Pvt. Ltd, New Delhi. Page no. -concerning medicine pages.
17. Bhanja KC. *Constitution, Drug Picture and Treatment*;; 1st ed. 1971. Published by Mrs. Santi Bhanja 38, Shubhasnagar 1st bye- lane Calcutta 28. Page no. - concerning medicine pages.
18. Boericke W. *Pocket manual of homoeopathic materia medica*. Reprint ed. 1998. B. Jain Publishers Pvt. Ltd, New Delhi. Page no. - concerning medicine pages.
19. Hay R. Therapy of Skin, Hair and Nail Fungal Infections. *J Fungi (Basel)*. 2018 Aug 20;4(3) [[PMC free article](#)] [[PubMed](#)]
20. Trocoli Drakensjö I, Vassilaki I, Bradley M. Majocchi Granuloma Caused by Trichophyton mentagrophytes in 2 Immunocompetent Patients. *Actas Dermosifiliogr*. 2017 Jan-Feb;108(1):e6-e8. [[PubMed](#)]
21. Mayser P. [Dermatophyte : Current situation]. *Hautarzt*. 2017 Apr;68(4):316-323. [[PubMed](#)]